Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (CMPS)
NASDAQ:CMPS
CMPS Stock Chart & Stats
$6.34
-$0.42(-9.17%)
At close: 4:00 PM EST
$6.34
-$0.42(-9.17%)
Day’s Range― - ―
52-Week Range$2.25 - $7.09
Previous CloseN/A
Volume477.34K
Average Volume (3M)1.56M
Market Cap
$608.31M
Enterprise Value$74.38M
Total Cash (Recent Filing)$222.26M
Total Debt (Recent Filing)$35.29M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Oct 30, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding95,941,260
10 Day Avg. Volume1,633,733
30 Day Avg. Volume1,561,498
Financial Highlights & Ratios
PEG Ratio1.91
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-2.14
Enterprise Value/Market Cap0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-465.28
Enterprise Value/Ebitda-0.53
Forecast
1Y Price Target
$18.43Price Target Upside190.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Earnings And Financial PositionCOMPASS ended the quarter with $221.9 million in cash, extending its runway into 2027 and enabling continued investment in TRD, PTSD, and commercial readiness.
Regulatory ProgressThere is optimism about the potential accelerated approval for new treatments for MDD and TRD, which could positively impact Compass Pathways.
Bears Say
Competitive LandscapeThere is concern about the competitive landscape with a promising rival drug from Gilgamesh that showed remarkable data, posing a potential threat.
Potential RisksThere is a potential risk of Serotonin Syndrome with the rival GM-2505 drug, which could change its risk-reward profile.
COMPASS Pathways News
CMPS FAQ
What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was $2.25 and its highest was $7.08 in the past 12 months.
What is COMPASS Pathways’s market cap?
COMPASS Pathways’s market cap is $608.31M.
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is Oct 30, 2025 which is in 6 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on Jul 31, 2025. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.433 by $0.023.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -0.4.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 95,941,260 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.433. Following the earnings report the stock price went up 10.406%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Currently, no hedge funds are holding shares in CMPS
COMPASS Pathways Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.43 (190.69% Upside)
$18.43 (190.69% Upside)
Blogger Sentiment
Neutral
CMPS Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 534.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.01%
12-Months-Change
Fundamentals
Return on Equity
-71.30%
Trailing 12-Months
Asset Growth
5.39%
Trailing 12-Months
Company Description
COMPASS Pathways
COMPASS Pathways (CMPS) is a mental health care company primarily focused on developing innovative therapies to address unmet needs in mental health. The company is at the forefront of researching and developing psychedelic-derived therapies, specifically focusing on psilocybin therapy, for the treatment of various mental health disorders such as treatment-resistant depression. With a strong emphasis on clinical research and trials, COMPASS Pathways aims to revolutionize the mental health landscape through evidence-based therapeutic options.
CMPS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally optimistic outlook for COMPASS Pathways, with significant positive results in late-stage trials and a strong financial position. However, challenges remain, particularly in achieving FDA approval and addressing trial dropouts.View all CMPS earnings summariesCMPS Stock 12 Month Forecast
Average Price Target
$18.43
▲(190.69% Upside)
Technical Analysis
Cross Country Healthcare
―
Oncology Institute
―
Talkspace
―
InnovAge Holding
―
Agilon Health
―
Ownership Overview
13.52% Insiders
0.45% Mutual Funds
<0.01% Other Institutional Investors
82.52% Public Companies and Individual Investors